You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Stroke
SBC: BioTime, Inc. Topic: 100ABSTRACT Stroke is a leading cause of disability worldwideGloballythere aremillion stroke survivors each year who have significant neurological deficits including sensory and motor disabilityleading to excessive socioeconomic burdenCell therapy using primary MSCs has been actively explored by us and others as a therapeutic solution to this unmet medical needHoweversince the therapeutic efficacy of ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Infant NeuroLUX: A Novel Non-invasive Therapeutic Device for Neonatal Hypoxic Brain Injury
SBC: Mitovation, Inc. Topic: 101Neonatal hypoxia ischemia is a known cause of cerebral damage resulting from inadequate blood flow and or oxygen delivery to the infant brain beforeduringor after birthThe occurrence among hospital deliveries isperfull term births with a drastic increase among premature newbornsThe deficit in oxygen delivery to the brain results in extensive damage and severe disabilitiesRestoration of blood flow ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Veristride STEP-R: an interactive verbal/auditory gait trainer
SBC: Veristride, Inc. Topic: 600Veristride IncProject Summary When surveyedof stroke survivors said the ability toget out and aboutis considered between important and essential for a better lifeHoweverthat desire falls short of reality for most stroke survivorsOftenwalking across a neighborhood street or from a car to a home is an insurmountable task with little opportunity for working on improvement in gaitOnce insurance covera ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Amelioration of rhinovirus induced asthma exacerbations by serpin B1
SBC: Serplus Technology, LLC Topic: NIAIDPROJECT SUMMARY Asthma exacerbations are a major cause of ER visits and hospitalizations with annual direct costs of approximately $billionyear in the USAViral infectionsin particular rhinoviralRVinfectionsare a major precipitant of asthma exacerbations in allergic asthmaticsAs there are overRV serotypes andfor nowno RV vaccinenovel strategies to inhibit RV induced airway inflammation are needed t ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Hybrid DNN-based Transfer Learning and CNN-based Supervised Learning for Object Recognition in Multi-modal Infrared Imagery
SBC: TOYON RESEARCH CORPORATION Topic: 1On this effort Toyon Research Corp. and The Pennsylvania State University are developing deep learning-based algorithms for object recognition and new class discovery in look-down infrared (IR) imagery. Our approach involves the development of a hybrid classifier that exploits both transfer learning and semi-supervised paradigms in order to maintain good generalization accuracy, especially when li ...
STTR Phase I 2018 Department of DefenseNational Geospatial-Intelligence Agency -
Algorithms for Look-down Infrared Target Exploitation
SBC: Signature Research, Inc. Topic: 1Signature Research, Inc. (SGR) and Michigan Technological University (MTU) propose a Phase I STTR effort to develop a learning algorithm which exploits the spatio-spectral characteristics inherent within IR imagery and motion imagery.Our archive of modelled and labeled data sets will allow our team to thoroughly capture the variable elements that will drive machine learning performance.The overall ...
STTR Phase I 2018 Department of DefenseNational Geospatial-Intelligence Agency -
A Novel Treatment for Acetominophen-Induced Liver Injury
SBC: MITOTHERAPEUTIX LLC Topic: 300Abstract The Specific Aim of this Phase I STTR proposal is to test the feasibility of blocking MCJalso called DnaJCto overcome acute acetaminophen liver toxicityAcetaminophen or APAPfrom acetyl paraaminophenolis a common drug used to address pain and feverIn the US aloneaboutpatients per year are admitted to intensive care units with APAP induced liver injury and close toof these patients undergo ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Developing an efficient E-cigarette aerosol generation and exposure system for rodent models with aerosol characteristics equivalent to those inhaled by E-cigarette users
SBC: AUTOMATE SCIENTIFIC, INC. Topic: NIDAAbstract E cigaretteE ciguse has rapidly proliferated worldwideIt is speculated that E cig use may exceed conventional cigarette use withinyearsCigarette smoking is the leading preventable cause of death and disabilityAs E cigs are a relatively new productstudies are needed to determine their long term detrimental effectssome of which may be similar to the long term detrimental effects of nicotine ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
The Kappa Partial Agonist PPL-103 as a Potential Cocaine Abuse Pharmacotherapy
SBC: PHOENIX PHARMALABS, INC. Topic: NIDAAbstract Currentlyclinically used drug abuse medications exist for treatment of addiction to opiatesalcoholand nicotinebut not cocaineThe objective of the proposed project is to test the hypothesis that the partial kappa agonist PPLcan be effective as a pharmacotherapy for treatment of cocaine abuseBecause of chronic drug induced changes in the kappa opioid receptor systemkappa receptor directed c ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity
SBC: SignalRx Pharmaceuticals Inc. Topic: 102Three CDKinhibitors were recently approved to treat breast cancerBrCAin combination regimentsDespite significant clinical activitytreatment of BrCA patients with these combinations does not result in a durable responseHencethere is an unmet medical need to develop targeted therapeutic agents which will augment the activity of CDKinhibitors in BrCA and other CDKcyclin D Myc dependent malignanciesA ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health